Company / R&D Expense
KIORA PHARMACEUTICALS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$7.8M
FY2025
5-year range
$3.6M / $8.1M
FY2021-FY2025
Trend
+94.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $4M to $8M over the past 4 years.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +7.8%.
Improved from $4M to $8M over the past 4 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +7.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +7.8%, indicating consistent growth.
- In FY2025, r&d expense increased 94.7% year-over-year.
- Peak r&d expense was recorded in FY2018.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -5.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.8M | +94.7% |
| FY2024 | $4.0M | +12.9% |
| FY2021 | $3.6M | -33.8% |
| FY2020 | $5.4M | -33.1% |
| FY2019 | $8.1M | -22.0% |
| FY2018 | $10.3M | +22.7% |
| FY2017 | $8.4M | +210.0% |
| FY2016 | $2.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026